Harvard Apparatus Regenerative Technology Inc. (HRGN)

Market Cap	31.65M -23.8%
Revenue (ttm)	743.00K +216.2%
Net Income	-6.53M
EPS	-0.40
Shares Out	17.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,057
Average Volume	5,998
Open	1.770
Previous Close	1.800
Day's Range	1.770 - 1.770
52-Week Range	0.936 - 2.550
Beta	-0.13
RSI	49.62
Earnings Date	Mar 30, 2026

About HRGN

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. The company’s pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, inclu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 8
• Stock Exchange: OTCMKTS
• Ticker Symbol: HRGN

Financial Performance

In 2024, HRGN's revenue was $430,000, an increase of 317.48% compared to the previous year's $103,000. Losses were -$7.73 million, -14.30% less than in 2023.